Concepedia

Peter P. Stein

PP

Statistics

Publications

18

Citations

5.5K

H-Index

17

Active since

1989

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Yale University

University of Oxford

Johnson & Johnson (United States)

Diabeteszentrum Bad Lauterberg

Peter P. Stein is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in clinical pharmacology, diabetes pharmacotherapy, and diabetes management.

Publications per year

1989–2015

18

Publications

18

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

, , +15

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

Michael A. Nauck, Gary Meininger, Lisa Terranella et al. · Diabetes Obesity and Metabolism · 2007 · 667 citations · Full text

, , +17

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

Itamar Raz, Yu Chen, Mei Wu et al. · Current Medical Research and Opinion · 2008 · 262 citations

, , +16

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

Juliana C.N. Chan, Russell Scott, Juan Camilo Arjona Ferreira et al. · Diabetes Obesity and Metabolism · 2008 · 238 citations

, , +16

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

Kenji Nonaka, Taro Kakikawa, Asako Sato et al. · Diabetes Research and Clinical Practice · 2008 · 206 citations

, , +12

1–5 of 18